Blue Jet plans Rs 1,000 crore Vizag CDMO Phase I platform

Blue Jet Healthcare Limited plans about Rs 1,000 crore of capital expenditure for Vizag Phase I, a multi-chemistry contract development and manufacturing organisation (CDMO) platform, while its Hyderabad research and development (R&D) centre is operational with about 50 scientists. Management said the two projects are intended to link early development work with commercial-scale manufacturing.

What is Blue Jet building at Vizag?

Blue Jet is developing Vizag Units 5 and 6 as an integrated pharmaceutical manufacturing facility on about 100 acres, with Phase I spanning contrast media, pharmaceutical intermediates, peptide fragments, high-intensity sweeteners and multipurpose blocks. Management described the site as its next major growth platform and said it is being designed to support several chemistry technologies, customers and product life cycles.

Phase I carries envisaged capital expenditure of about Rs 1,000 crore, and pre-construction activities are under way. Environmental clearance (EC) and Consent to Establish approvals are in place, according to management. Blue Jet did not provide a construction-completion date or a commercial-production date for the first phase.

The proposed site is intended to incubate early-stage programmes and graduate them into commercial manufacturing, including a couple of lateral transfers. Management said the principal volume from these lateral-transfer opportunities would come after Vizag begins operations, although existing capacity could be used if bridging production is required.

Mahad Unit 3 has a narrower purpose than Vizag: it is being built to manufacture a strategically important key starting material (KSM) for contrast media. Its planned backward integration covers the relevant part of that value chain, while Vizag combines multiple product categories and flexible manufacturing blocks.

How does Hyderabad R&D support Blue Jet’s CDMO plan?

Blue Jet’s Hyderabad R&D centre is operational, with development activities started and about 50 scientists onboarded. The site includes synthesis laboratories and an analytical facility, and management said it is intended to support customers from early-stage process development through scale-up and commercial manufacturing.

The Hyderabad project is planned to add about 100 fume hoods across two phases to Blue Jet’s existing R&D capacity. Management identified flow synthesis, peptides, good laboratory practice (GLP)-related intermediates, biocatalysis, high-potency products and solid-phase chemistry as new platform areas for the facility.

Management said the centre should improve the company’s response time to increasing requests for proposals, while Vizag is intended to provide the manufacturing route for successful programmes. The stated model links development, scale-up and production rather than treating the R&D centre as a standalone laboratory investment.

During Q2 FY27, Blue Jet delivered and validated a new contrast-media intermediate for an innovator and reported similar progress on a peptide fragment for another innovator company. Management said both opportunities were in the clinical phase, so it did not disclose revenue contribution, market size or a commercial ramp-up schedule.

How is Blue Jet financing the expansion projects?

Blue Jet said its qualified institutional placement (QIP) raised Rs 800 crore for capital expenditure, working capital and general corporate purposes. Management said the proceeds would be deployed in phases over the next three years, as indicated in the offer document.

At Mahad Unit 3, Blue Jet had spent about Rs 250 crore as of the November 5, 2026 earnings call and remained on track for the facility to go on stream in the second half of FY27. Management said the KSM project should provide supply security and cost competitiveness in the relevant contrast-media value chain.

The investment programme follows Q2 FY27 revenue from operations of Rs 375 crore, up 28% from the prior quarter. Management attributed sequential growth of 25% to contrast media and 52% to pharmaceutical intermediates and active pharmaceutical ingredients, while artificial sweeteners declined 30% from the preceding quarter.

Q2 FY27 gross margin was 49%, down 4 percentage points sequentially, and earnings before interest, tax, depreciation and amortisation (EBITDA) were Rs 119 crore, equal to 32% of operating revenue and down 1 percentage point sequentially. Management attributed the margin movement to higher reagent, solvent and catalyst costs following disruption in West Asia, alongside the timing of inventory consumption and customer price adjustments.

What operating evidence supports the broader platform strategy?

Blue Jet reported its fourth consecutive quarter of sequential growth in Q2 FY27, when management cited revenue of about Rs 376 crore and EBITDA of about Rs 119 crore as its highest quarterly levels. Management linked the operating momentum to existing contrast-media and pharmaceutical-intermediate programmes while pursuing the broader CDMO build-out.

For H1 FY27, Blue Jet reported revenue of Rs 669 crore, a 29% increase from H1 FY26. Contrast media grew 47%, pharmaceutical intermediates and active pharmaceutical ingredients grew 19%, and artificial sweeteners declined 2%, showing that growth was concentrated in the first two businesses.

H1 FY27 EBITDA was Rs 217 crore, or 32% of operating income, while profit after tax was Rs 181 crore, or 27% of total income. EBITDA margin declined 2 percentage points and profit-after-tax margin declined 1 percentage point from H1 FY26; management cited headcount additions and certain logistics costs for the lower percentages despite absolute profit growth.

Blue Jet also said renewable energy accounted for about 80% of its overall consumption and that it had received a silver EcoVadis rating. The call did not quantify a financial effect from either the renewable-energy share or the sustainability rating.

Conclusion

The Vizag plan, Hyderabad R&D launch and Mahad backward-integration project outline Blue Jet’s effort to combine differentiated chemistry development with commercial manufacturing across more than one product category. The approach is supported by H1 FY27 revenue growth of 29%, but the clinical-stage contrast-media and peptide opportunities remain subject to regulatory and commercial progression.

The next disclosed milestones are Mahad Unit 3 going on stream in H2 FY27, phased use of the Rs 800 crore QIP proceeds over three years, and further progress at Vizag beyond pre-construction. Management also said selected customer price increases would take effect from Q3, making input-cost movements, product mix and price-adjustment timing relevant to gross-margin performance.